Global Premenstrual Dysphoric Disorder Market

Premenstrual Dysphoric Disorder Comprehensive Study by Treatment (Antidepressants, Contraceptives, Over-the-counter Pain Relievers, Cognitive Therapy, Other Medicines), End-users (Hospitals, Clinics, Others), Distribution Channel (Online Channel, Offline Channel) Players and Region - Global Market Outlook to 2026

Premenstrual Dysphoric Disorder Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The premenstrual dysphoric disorder is a health problem in which a woman has severe depression symptoms, irritability, and tension before menstruation. It is similar to premenstrual syndrome (PMS), but it is more serious. It causes severe irritability, depression or anxiety in a week or two before the period starts. The causes of premenstrual dysphoric disorder are unknown. It may be due to hormone changes that occur during a woman's menstrual cycle. The other factors that may play a role involve alcohol abuse, thyroid disorders, being overweight and lack of exercise.This growth is primarily driven by Increased Prevalence of Premenstrual Dysphoric Disorder, Changing Lifestyle of the People and Increased Obesity in Females.

Globally, a noticeable market trend is evident Development of New Hospitals and Diagnostics Centres. Major Players, such as Bristol Laboratories (United Kingdom), Pfizer Inc. (United States), Medline Industries, Inc. (United States), Mylan N.V. (United States), Almatica Pharmaceuticals (United States), Lupin Pharmaceuticals, Inc. (India), Allergan plc (Ireland), Teva Pharmaceuticals (Israel), Eli Lilly and Company (United States) and Bayer AG (Germany) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In June 2019, Pfizer Inc. and Array BioPharma Inc. has announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.

Market Drivers
  • Increased Prevalence of Premenstrual Dysphoric Disorder
  • Changing Lifestyle of the People
  • Increased Obesity in Females

Market Trend
  • Development of New Hospitals and Diagnostics Centres

Restraints
  • Lack of Proper Treatment

Opportunities
Growing Healthcare Industry Worldwide and Increasing Female Population
Challenges
Less Awareness among Some Regions

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Premenstrual Dysphoric Disorder Study Sheds Light on
— The Premenstrual Dysphoric Disorder Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Premenstrual Dysphoric Disorder industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Premenstrual Dysphoric Disorder industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Treatment
  • Antidepressants
  • Contraceptives
  • Over-the-counter Pain Relievers
  • Cognitive Therapy
  • Other Medicines

By End-users
  • Hospitals
  • Clinics
  • Others

By Distribution Channel
  • Online Channel
  • Offline Channel

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Premenstrual Dysphoric Disorder
      • 3.2.2. Changing Lifestyle of the People
      • 3.2.3. Increased Obesity in Females
    • 3.3. Market Challenges
      • 3.3.1. Less Awareness among Some Regions
    • 3.4. Market Trends
      • 3.4.1. Development of New Hospitals and Diagnostics Centres
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Premenstrual Dysphoric Disorder, by Treatment, End-users, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Premenstrual Dysphoric Disorder (Value)
      • 5.2.1. Global Premenstrual Dysphoric Disorder by: Treatment (Value)
        • 5.2.1.1. Antidepressants
        • 5.2.1.2. Contraceptives
        • 5.2.1.3. Over-the-counter Pain Relievers
        • 5.2.1.4. Cognitive Therapy
        • 5.2.1.5. Other Medicines
      • 5.2.2. Global Premenstrual Dysphoric Disorder by: End-users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Premenstrual Dysphoric Disorder by: Distribution Channel (Value)
        • 5.2.3.1. Online Channel
        • 5.2.3.2. Offline Channel
      • 5.2.4. Global Premenstrual Dysphoric Disorder Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Premenstrual Dysphoric Disorder: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol Laboratories (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Medline Industries, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan N.V. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Almatica Pharmaceuticals (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Lupin Pharmaceuticals, Inc. (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Allergan plc (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceuticals (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bayer AG (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Premenstrual Dysphoric Disorder Sale, by Treatment, End-users, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Premenstrual Dysphoric Disorder (Value)
      • 7.2.1. Global Premenstrual Dysphoric Disorder by: Treatment (Value)
        • 7.2.1.1. Antidepressants
        • 7.2.1.2. Contraceptives
        • 7.2.1.3. Over-the-counter Pain Relievers
        • 7.2.1.4. Cognitive Therapy
        • 7.2.1.5. Other Medicines
      • 7.2.2. Global Premenstrual Dysphoric Disorder by: End-users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Premenstrual Dysphoric Disorder by: Distribution Channel (Value)
        • 7.2.3.1. Online Channel
        • 7.2.3.2. Offline Channel
      • 7.2.4. Global Premenstrual Dysphoric Disorder Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Premenstrual Dysphoric Disorder: by Treatment(USD Million)
  • Table 2. Premenstrual Dysphoric Disorder Antidepressants , by Region USD Million (2015-2020)
  • Table 3. Premenstrual Dysphoric Disorder Contraceptives , by Region USD Million (2015-2020)
  • Table 4. Premenstrual Dysphoric Disorder Over-the-counter Pain Relievers , by Region USD Million (2015-2020)
  • Table 5. Premenstrual Dysphoric Disorder Cognitive Therapy , by Region USD Million (2015-2020)
  • Table 6. Premenstrual Dysphoric Disorder Other Medicines , by Region USD Million (2015-2020)
  • Table 7. Premenstrual Dysphoric Disorder: by End-users(USD Million)
  • Table 8. Premenstrual Dysphoric Disorder Hospitals , by Region USD Million (2015-2020)
  • Table 9. Premenstrual Dysphoric Disorder Clinics , by Region USD Million (2015-2020)
  • Table 10. Premenstrual Dysphoric Disorder Others , by Region USD Million (2015-2020)
  • Table 11. Premenstrual Dysphoric Disorder: by Distribution Channel(USD Million)
  • Table 12. Premenstrual Dysphoric Disorder Online Channel , by Region USD Million (2015-2020)
  • Table 13. Premenstrual Dysphoric Disorder Offline Channel , by Region USD Million (2015-2020)
  • Table 14. South America Premenstrual Dysphoric Disorder, by Country USD Million (2015-2020)
  • Table 15. South America Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 16. South America Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 17. South America Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 18. Brazil Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 19. Brazil Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 20. Brazil Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 21. Argentina Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 22. Argentina Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 23. Argentina Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 24. Rest of South America Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 25. Rest of South America Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 26. Rest of South America Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 27. Asia Pacific Premenstrual Dysphoric Disorder, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 29. Asia Pacific Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 30. Asia Pacific Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 31. China Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 32. China Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 33. China Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 34. Japan Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 35. Japan Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 36. Japan Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 37. India Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 38. India Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 39. India Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 40. South Korea Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 41. South Korea Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 42. South Korea Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 43. Taiwan Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 44. Taiwan Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 45. Taiwan Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 46. Australia Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 47. Australia Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 48. Australia Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 52. Europe Premenstrual Dysphoric Disorder, by Country USD Million (2015-2020)
  • Table 53. Europe Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 54. Europe Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 55. Europe Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 56. Germany Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 57. Germany Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 58. Germany Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 59. France Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 60. France Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 61. France Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 62. Italy Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 63. Italy Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 64. Italy Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 65. United Kingdom Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 66. United Kingdom Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 67. United Kingdom Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 68. Netherlands Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 69. Netherlands Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 70. Netherlands Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 71. Rest of Europe Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 72. Rest of Europe Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 73. Rest of Europe Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 74. MEA Premenstrual Dysphoric Disorder, by Country USD Million (2015-2020)
  • Table 75. MEA Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 76. MEA Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 77. MEA Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 78. Middle East Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 79. Middle East Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 80. Middle East Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 81. Africa Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 82. Africa Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 83. Africa Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 84. North America Premenstrual Dysphoric Disorder, by Country USD Million (2015-2020)
  • Table 85. North America Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 86. North America Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 87. North America Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 88. United States Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 89. United States Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 90. United States Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 91. Canada Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 92. Canada Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 93. Canada Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 94. Mexico Premenstrual Dysphoric Disorder, by Treatment USD Million (2015-2020)
  • Table 95. Mexico Premenstrual Dysphoric Disorder, by End-users USD Million (2015-2020)
  • Table 96. Mexico Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2015-2020)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Premenstrual Dysphoric Disorder: by Treatment(USD Million)
  • Table 108. Premenstrual Dysphoric Disorder Antidepressants , by Region USD Million (2021-2026)
  • Table 109. Premenstrual Dysphoric Disorder Contraceptives , by Region USD Million (2021-2026)
  • Table 110. Premenstrual Dysphoric Disorder Over-the-counter Pain Relievers , by Region USD Million (2021-2026)
  • Table 111. Premenstrual Dysphoric Disorder Cognitive Therapy , by Region USD Million (2021-2026)
  • Table 112. Premenstrual Dysphoric Disorder Other Medicines , by Region USD Million (2021-2026)
  • Table 113. Premenstrual Dysphoric Disorder: by End-users(USD Million)
  • Table 114. Premenstrual Dysphoric Disorder Hospitals , by Region USD Million (2021-2026)
  • Table 115. Premenstrual Dysphoric Disorder Clinics , by Region USD Million (2021-2026)
  • Table 116. Premenstrual Dysphoric Disorder Others , by Region USD Million (2021-2026)
  • Table 117. Premenstrual Dysphoric Disorder: by Distribution Channel(USD Million)
  • Table 118. Premenstrual Dysphoric Disorder Online Channel , by Region USD Million (2021-2026)
  • Table 119. Premenstrual Dysphoric Disorder Offline Channel , by Region USD Million (2021-2026)
  • Table 120. South America Premenstrual Dysphoric Disorder, by Country USD Million (2021-2026)
  • Table 121. South America Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 122. South America Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 123. South America Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 124. Brazil Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 125. Brazil Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 126. Brazil Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 127. Argentina Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 128. Argentina Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 129. Argentina Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 130. Rest of South America Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 131. Rest of South America Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 132. Rest of South America Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 133. Asia Pacific Premenstrual Dysphoric Disorder, by Country USD Million (2021-2026)
  • Table 134. Asia Pacific Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 135. Asia Pacific Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 136. Asia Pacific Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 137. China Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 138. China Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 139. China Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 140. Japan Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 141. Japan Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 142. Japan Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 143. India Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 144. India Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 145. India Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 146. South Korea Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 147. South Korea Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 148. South Korea Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 149. Taiwan Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 150. Taiwan Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 151. Taiwan Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 152. Australia Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 153. Australia Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 154. Australia Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 158. Europe Premenstrual Dysphoric Disorder, by Country USD Million (2021-2026)
  • Table 159. Europe Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 160. Europe Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 161. Europe Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 162. Germany Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 163. Germany Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 164. Germany Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 165. France Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 166. France Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 167. France Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 168. Italy Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 169. Italy Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 170. Italy Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 171. United Kingdom Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 172. United Kingdom Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 173. United Kingdom Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 174. Netherlands Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 175. Netherlands Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 176. Netherlands Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 177. Rest of Europe Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 178. Rest of Europe Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 179. Rest of Europe Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 180. MEA Premenstrual Dysphoric Disorder, by Country USD Million (2021-2026)
  • Table 181. MEA Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 182. MEA Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 183. MEA Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 184. Middle East Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 185. Middle East Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 186. Middle East Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 187. Africa Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 188. Africa Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 189. Africa Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 190. North America Premenstrual Dysphoric Disorder, by Country USD Million (2021-2026)
  • Table 191. North America Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 192. North America Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 193. North America Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 194. United States Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 195. United States Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 196. United States Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 197. Canada Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 198. Canada Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 199. Canada Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 200. Mexico Premenstrual Dysphoric Disorder, by Treatment USD Million (2021-2026)
  • Table 201. Mexico Premenstrual Dysphoric Disorder, by End-users USD Million (2021-2026)
  • Table 202. Mexico Premenstrual Dysphoric Disorder, by Distribution Channel USD Million (2021-2026)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Premenstrual Dysphoric Disorder: by Treatment USD Million (2015-2020)
  • Figure 5. Global Premenstrual Dysphoric Disorder: by End-users USD Million (2015-2020)
  • Figure 6. Global Premenstrual Dysphoric Disorder: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Premenstrual Dysphoric Disorder Share (%), by Country
  • Figure 8. Asia Pacific Premenstrual Dysphoric Disorder Share (%), by Country
  • Figure 9. Europe Premenstrual Dysphoric Disorder Share (%), by Country
  • Figure 10. MEA Premenstrual Dysphoric Disorder Share (%), by Country
  • Figure 11. North America Premenstrual Dysphoric Disorder Share (%), by Country
  • Figure 12. Global Premenstrual Dysphoric Disorder share by Players 2020 (%)
  • Figure 13. Global Premenstrual Dysphoric Disorder share by Players (Top 3) 2020(%)
  • Figure 14. Global Premenstrual Dysphoric Disorder share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Bristol Laboratories (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. Bristol Laboratories (United Kingdom) Revenue: by Geography 2020
  • Figure 18. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 20. Medline Industries, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Medline Industries, Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 24. Almatica Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 25. Almatica Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 26. Lupin Pharmaceuticals, Inc. (India) Revenue, Net Income and Gross profit
  • Figure 27. Lupin Pharmaceuticals, Inc. (India) Revenue: by Geography 2020
  • Figure 28. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 29. Allergan plc (Ireland) Revenue: by Geography 2020
  • Figure 30. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 31. Teva Pharmaceuticals (Israel) Revenue: by Geography 2020
  • Figure 32. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 33. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 34. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 36. Global Premenstrual Dysphoric Disorder: by Treatment USD Million (2021-2026)
  • Figure 37. Global Premenstrual Dysphoric Disorder: by End-users USD Million (2021-2026)
  • Figure 38. Global Premenstrual Dysphoric Disorder: by Distribution Channel USD Million (2021-2026)
  • Figure 39. South America Premenstrual Dysphoric Disorder Share (%), by Country
  • Figure 40. Asia Pacific Premenstrual Dysphoric Disorder Share (%), by Country
  • Figure 41. Europe Premenstrual Dysphoric Disorder Share (%), by Country
  • Figure 42. MEA Premenstrual Dysphoric Disorder Share (%), by Country
  • Figure 43. North America Premenstrual Dysphoric Disorder Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bristol Laboratories (United Kingdom)
  • Pfizer Inc. (United States)
  • Medline Industries, Inc. (United States)
  • Mylan N.V. (United States)
  • Almatica Pharmaceuticals (United States)
  • Lupin Pharmaceuticals, Inc. (India)
  • Allergan plc (Ireland)
  • Teva Pharmaceuticals (Israel)
  • Eli Lilly and Company (United States)
  • Bayer AG (Germany)
Additional players considered in the study are as follows:
Select User Access Type

Key Highlights of Report


Sep 2021 215 Pages 62 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Premenstrual Dysphoric Disorder Market Quantitative research analysis
Global Premenstrual Dysphoric Disorder Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Premenstrual Dysphoric Disorder Market are Bristol Laboratories (United Kingdom), Pfizer Inc. (United States), Medline Industries, Inc. (United States), Mylan N.V. (United States), Almatica Pharmaceuticals (United States), Lupin Pharmaceuticals, Inc. (India), Allergan plc (Ireland), Teva Pharmaceuticals (Israel), Eli Lilly and Company (United States) and Bayer AG (Germany) etc.
The premenstrual dysphoric disorder is a health problem in which a woman has severe depression symptoms, irritability, and tension before menstruation. It is similar to premenstrual syndrome (PMS), but it is more serious. It causes severe irritability, depression or anxiety in a week or two before the period starts. The causes of premenstrual dysphoric disorder are unknown. It may be due to hormone changes that occur during a woman's menstrual cycle. The other factors that may play a role involve alcohol abuse, thyroid disorders, being overweight and lack of exercise.

Know More About Global Premenstrual Dysphoric Disorder Market Report?

Have a Query? Click Here

Other Related Reports

Systemic Mastocytosis Treatments Comprehensive Study by Type (AK-002, BLU-285, Brentuximab Vedotin, Crenolanib Besylate, Cromolyn Sodium, Others), Application (Clinic, Hospital, Homecare, Others), Te...
$ 3650
Allergy Medications Comprehensive Study by Type (Pills, Liquids, Inhalers, Nasal Sprays, Eyedrops, Skin Creams, Others), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmac...
$ 3350
Osteonecrosis Comprehensive Study by Application (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers), Diagnoses Used (X-Ray, MRI, Bone Scans, Ct Scan, Surgical Procedures), Route of Administ...
$ 3750
Influenza Treatment Comprehensive Study by Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, Others), Diagnostic Tests (Viral culture, Serology, Rapid antigen testing, Reverse tr...
$ 3750
Topical Use Acne Treatment Comprehensive Study by Type (Inflammatory Acne, Cystic Acne, Post-Surgical/Wound Acne), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Drug Type (...
$ 3750
Sacroiliitis Treatment Comprehensive Study by Type (Medication, Pain relievers, Muscle relaxants, TNF inhibitors, Joint Injections, Radiofrequency denervation, Electrical stimulation, Joint fusion), ...
$ 3450